Niagen® (patented nicotinamide riboside) may reduce production of inflammatory cytokines in pilot study of Stage D heart failure patients LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. A NIH funded study […]